凯因科技撤回乙肝适应症药品申请，2025年利润减少1.11亿元

Core Viewpoint - Kaiyin Technology has withdrawn its drug registration application for Peginterferon α-2 Injection (new hepatitis B indication), which is expected to reduce its profit by approximately 111 million yuan in 2025 [1] Group 1: Company Actions - On January 20, 2026, Kaiyin Technology (688687.SH) announced the withdrawal of its drug registration application for Peginterferon α-2 Injection, which is already approved for treating chronic hepatitis C [1] - The company decided to withdraw the application based on the latest review suggestions from the National Medical Products Administration, indicating a need for further clinical case studies before resubmission [1] Group 2: Financial Impact - The withdrawal of the drug registration application will lead to a full impairment provision for the related development expenses, resulting in a reduction of approximately 111 million yuan in the total profit for the year 2025 [1] - For the first three quarters of 2025, Kaiyin Technology reported a revenue of 927 million yuan and a total profit of 131 million yuan, highlighting the significant impact this withdrawal will have on the company's overall performance for the year [1]